Akinesia News and Research

RSS

What role does dysbiosis play in Parkinson's disease?

The current study, published in the journal Revue Neurologique, is based on the hypothesis that dysbiosis, or unhealthy variations in the gut and oral microbiota, is a key component of PD pathogenesis.

19 Mar 2023

Study reveals link between changes of neuronal activities and dyskinesia

Many people with Parkinson's disease develop abnormal movements called L-DOPA induced dyskinesia, a major side effect of long-term medication. The mechanism underlying this side effect has been unknown. In this study, researchers have revealed relation between changes of neuronal activities and dyskinesia.

9 Apr 2021

Medicinal cannabis improves outcomes in Parkinson's patients

With medicinal cannabis now legalized in many parts of the world, there is growing interest in its use to alleviate symptoms of many illnesses including Parkinson's disease (PD).

27 Jan 2021

Anti-diabetic drug could be repurposed for treating Parkinson's disease

A hallmark of Parkinson's disease is the degeneration of a group of dopaminergic neurons in the brain, which play key roles in movement initiation and co-ordination.

24 Nov 2020

Phase–amplitude coupling changes may underlie DBS success in parkinsonism

Deep-brain stimulation of the subthalamic nucleus may improve motor symptoms in patients with Parkinson’s disease by reducing excessive cortical phase–amplitude coupling, researchers report in Nature Neuroscience.

14 Apr 2015

Electrode placement affects subthalamic nucleus stimulation outcomes

Researchers have identified factors associated with motor, cognitive and mood outcomes after deep-brain stimulation (DBS) of the subthalamic nucleus in a large cohort of patients with Parkinson’s disease.

4 Apr 2014

Dopamine improves long-term memory

The feel-good hormone dopamine improves long-term memory. This is the finding of a team lead by Emrah D-zel, neuroscientist at the German Center for Neurodegenerative Diseases and the University of Magdeburg.

9 Nov 2012

Administering vitamin K2 could possibly help patients with Parkinson's

Neuroscientist Patrik Verstreken, associated with VIB and KU Leuven, succeeded in undoing the effect of one of the genetic defects that leads to Parkinson's using vitamin K2. His discovery gives hope to Parkinson's patients.

11 May 2012

Risk of Parkinson's disease increases with traumatic brain injury and exposure to pesticide paraquat

Traumatic brain injury has entered the public's consciousness as the silent, signature wound brought back by many of our military warriors from Iraq and Afghanistan. But such injuries don't only happen in warfare, they happen to civilians too. Think car crashes, a slip and fall, two football players colliding helmet to helmet.

22 Aug 2011

Intra-Cellular Therapies demonstrates ability of ITI-002 to improve motor and non-motor behaviors in PD

Intra-Cellular Therapies, Inc. today announced results from studies demonstrating the anti-Parkinson and other beneficial effects of ITI-002 (IC200214), the Company's novel and selective phosphodiesterase type I (PDE1) inhibitor.

1 Oct 2010

Evaluation of medical reasons behind end to pregnancy due to abnormalities of fetus important

When a pregnancy ends tragically due to fatal abnormalities of the fetus, it is important to understand the medical reasons behind the event. This evaluation can help predict the risk of reoccurrence in future pregnancies. In the case of fetal akinesia deformation sequence (FADS), the fetus may have been affected by a disrupting injury or unavoidable maldevelopment.

18 Aug 2010

St. Jude Medical announces first European patient implants of Libra deep brain stimulation systems for Parkinson’s Disease

St. Jude Medical, Inc. has announced the first patient implants of its Libra deep brain stimulation (DBS) system for treating the symptoms of Parkinson's disease, a progressive neurological disorder that affects a person's control over his or her movements and speech.

29 Mar 2009

Safinamide significantly improved motor function in patients with advanced Parkinson's disease

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its partner Newron Pharmaceuticals SpA has announced that the first Phase III trial of investigational agent safinamide as adjunctive therapy to levodopa (study 016) met its primary endpoint by increasing daily "ON" time in mid- to late-stage Parkinson's disease patients with motor fluctuations by 1.3 hours.

5 Feb 2009